American Pharma Names Heller CEO
506057
Injectable products maker American Pharmaceutical Partners Inc. said Thursday that it named Alan L. Heller as president and chief executive officer, effective immediately, and expects to appoint him as a director at the company&#39;s next annual meeting.
511625
Retiring Rep. Billy Tauzin will become head of the pharmaceutical industry's top lobbying group next month after leaving his post as head of the House committee that regulates the pharmaceutical industry.
482241
The drugmaker bumps into the FDA as it pushes to do more testing of Entereg.
124424
Retiring U.S. Rep. Billy Tauzin, who left his post as head of the House committee that regulates the pharmaceutical industry earlier this year, will become head of the industry's top lobbying group next month.
318366
Retiring Rep. Billy Tauzin, who once led the House committee that oversees drug makers and helped write the bill to expand Medicare prescription coverage, will become the head
494627
An interview with development-stage drugmaker Pharmacopeia.
17097
The generic drug maker&#39;s deal to buy King Pharmaceuticals was supposed to mark its arrival in the brand-name drug business. Instead, it put the spotlight on a new CEO&#39;s strategy that billionaire investor Carl Icahn doesn&#39;t like.
739756
The Massachusetts Hospital Association yesterday selected Lynn B. Nicholas , former head of the American Diabetes Association, to be chief executive of the statewide organization, which lobbies for hospitals and other healthcare providers.
180717
ARLINGTON, Va., Feb. 12  /PRNewswire/ -- The American Chemistry Council (ACC) today announced the election of Andrew N. Liveris, chairman and chief executive officer of The Dow Chemical Company, as its new Chairman of the Board.
423544
Retiring Rep. Billy Tauzin, who led the House committee that regulates drug makers, will become head of the industry's top lobbying group next month.
680034
An executive of the company that makes the diabetes drug Avandia said a researcher who was among the first to link it to heart problems would be held liable for the $4 billion GlaxoSmithKline PLC lost in stock value as a result of his findings, Dr. John B. Buse testified before congressional investigators yesterday.
387736
Eli Lilly and Co  said on Tuesday chief executive Sidney Taurel will retire on March 31, turning the reins over to Chief Operating Officer John Lechleiter as the drugmaker prepares for tough times ahead.
15160
The Swiss pharmaceutical company Roche Holding said its chief executive would step down next March as the company separates that job from the chairmanâs position. Franz B. Humer, who has been chief since 1998, will remain chairman of the board. Next July, he also will become chairman of the beverage company Diageo. He will be succeeded by Severin Schwan, 40, who had been the head of Rocheâs diagnostics unit since January. The company also posted a 24 percent increase in first-half net profit, to 4.92 billion Swiss francs ($4.1 billion) from 3.97 billion francs in the period a year earlier. Roche benefited from its flu treatment Tamiflu as governments stockpile the drug in case of an influenza pandemic.
44172
Biotech giant Inc. Amgen and the pharmaceuticals division of health-care products company Wyeth said Tuesday the Food and Drug Administration approved their arthritis treatment Enbrel to induce a major clinical
239964
NEW YORK (Dow Jones/AP) -- Video-game maker Atari Inc. said Monday it named James Caparro president and chief executive officer, effective immediately.
495468
When questions are raised about the heart safety of drugs used by millions, Dr. Steven E. Nissen often raises a red flag. Nissen, chairman of the Cleveland Clinic's department of cardiovascular medicine and an outside adviser to the Food and Drug Administration, calls himself the "point on the end of the spear" during drug safety debates. Nissen spoke with Globe ...
254969
CEOs in the life-sciences business are supposed to be sober, scientifically grounded leaders. So, when Josh Boger, chief executive of Vertex Pharmaceuticals Inc. , showed a slide last year comparing one of the drugs his Cambridge company is developing to Apple's iPod, he raised a lot of eyebrows.